Ligand Pharmaceuticals Inc (LGND)
68.61
-3.86
(-5.33%)
USD |
NASDAQ |
Apr 22, 16:00
68.48
-0.14
(-0.20%)
After-Hours: 20:00
Ligand Pharmaceuticals Cash from Financing (TTM): -59.95M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -59.95M |
| September 30, 2023 | -70.56M |
| June 30, 2023 | -114.66M |
| March 31, 2023 | -106.34M |
| December 31, 2022 | -275.99M |
| September 30, 2022 | -266.53M |
| June 30, 2022 | -226.08M |
| March 31, 2022 | -216.55M |
| December 31, 2021 | -137.76M |
| September 30, 2021 | -169.45M |
| June 30, 2021 | -172.78M |
| March 31, 2021 | -122.88M |
| December 31, 2020 | -310.54M |
| September 30, 2020 | -366.71M |
| June 30, 2020 | -574.32M |
| March 31, 2020 | -611.90M |
| December 31, 2019 | -485.17M |
| September 30, 2019 | -748.56M |
| June 30, 2019 | -478.34M |
| March 31, 2019 | 172.78M |
| December 31, 2018 | 328.58M |
| September 30, 2018 | 668.42M |
| June 30, 2018 | 610.90M |
| March 31, 2018 | -2.632M |
| December 31, 2017 | -7.523M |
| Date | Value |
|---|---|
| September 30, 2017 | -8.871M |
| June 30, 2017 | -8.646M |
| March 31, 2017 | -7.172M |
| December 31, 2016 | -4.994M |
| September 30, 2016 | 5.079M |
| June 30, 2016 | 4.91M |
| March 31, 2016 | 8.09M |
| December 31, 2015 | 8.36M |
| September 30, 2015 | -22.10M |
| June 30, 2015 | 138.75M |
| March 31, 2015 | 131.05M |
| December 31, 2014 | 130.02M |
| September 30, 2014 | 156.36M |
| June 30, 2014 | -8.01M |
| March 31, 2014 | -7.311M |
| December 31, 2013 | -16.46M |
| September 30, 2013 | -10.56M |
| June 30, 2013 | -7.073M |
| March 31, 2013 | -4.632M |
| December 31, 2012 | 3.916M |
| September 30, 2012 | 0.733M |
| June 30, 2012 | -0.704M |
| March 31, 2012 | 4.214M |
| December 31, 2011 | 30.00M |
| September 30, 2011 | 29.77M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-748.56M
Minimum
Sep 2019
-59.95M
Maximum
Dec 2023
-290.27M
Average
-226.08M
Median
Jun 2022
Cash from Financing (TTM) Benchmarks
| ANI Pharmaceuticals Inc | 67.44M |
| ADMA Biologics Inc | -38.99M |
| Viking Therapeutics Inc | 271.38M |
| Corcept Therapeutics Inc | -148.72M |
| Palatin Technologies Inc | 5.553M |